OPINION
¶ 1 In this medical malpractice action, Allen Benkendorf appeals from a judgment entered following a jury verdict in favor of Advanced Cardiac Specialists Chartered (“ACSC”). The sole question we address in this opinion is whether the trial court should have prohibited ACSC from presenting expert testimony opining as to possible causes of an injury that led to a patient’s death. 1 For the following reasons, we hold that the court did not abuse its discretion in allowing such testimony.
BACKGROUND
¶ 2 Benkendorfs wife, Judy, underwent surgery in January 2003 to remove her cancerous left kidney. After the surgery, she developed a blood clot that went to her lung. Her doctor prescribed Coumadin, an anticoagulant medication that a patient takes orally. 2 Thereafter, Judy began regular visits to ACSC’s Coumadin Clinic, where her blood was tested and Coumadin dosage changed if necessary to maintain her therapeutic level. Early in the morning of June 16, 2003, Judy suffered an intracranial hemorrhage while at her home and died two days later.
¶ 3 Benkendorf sued ACSC, alleging it caused Judy’s death by negligently monitoring and adjusting her Coumadin dosages. Before trial, Benkendorf filed a motion in limine, seeking to preclude testimony from ACSC’s causation expert, Dr. Kurt Schroeder, regarding various possible causes of Judy’s death. Benkendorf asserted that Sehroeder’s “possibility” testimony was inadmissible because “experts can only testify about causation to a reasonable degree of medical probability.” After Schroeder’s second deposition confirmed that his opinions included possible causes of Judy’s death, Benkendorf filed a supplemental motion in limine, reiterating that a causation expert in a medical malpractice ease must testify about probabilities, not possibilities. The trial court denied Benkendorfs motion.
¶ 4 At trial, Benkendorf presented expert testimony that ACSC fell below the standard of care by failing to (1) withhold one Couma-din dose immediately after a test had revealed high INR levels; (2) lower Judy’s dosage in light of such information; and (3) cheek her INR levels again within the ensuing two or three days. Benkendorfs causation expert testified that ACSC’s failure to “bring [Judy’s] INR level back into a therapeutic range [was] the cause of her bleeding and death.” ACSC countered in part by presenting Schroeder’s videotaped deposition testimony. In that testimony, Sehroeder opined that Coumadin did not cause Judy’s hemorrhage, although he acknowledged that it exacerbated the bleeding once the hemorrhage began. Sehroeder further testified that even if Judy’s INR level had been within *530 the therapeutic range when she suffered the hemorrhage, the “outcome” would “[pjroba-bly” have been the same. Sehroeder also testified that any number of other factors could have caused Judy’s brain hemorrhage, including most notably her age, her hypertension, her removed kidney tumor, or her possible history of a stroke. 3
¶ 5 The jury returned a general verdict in favor of ACSC. After Benkendorf unsuccessfully moved for a new trial, the court entered judgment. This timely appeal followed.
DISCUSSION
¶ 6 Benkendorf asserts the trial court erred when it denied his motion in limine, because “Dr. Sehroeder’s ‘possibility’ testimony exceeded allowable trial testimony on probability.” He argues that expert testimony in medical malpractice cases must be carefully restricted and that experts must “testify about the probable causes of a medical injury — not about causes that are merely possible.” According to Benkendorf, without such a restriction, testimony about possible causes “is as unhelpful as saying ‘anything is possible.’ ”
¶ 7 We review the trial court’s order denying Benkendorfs motion in limine for an abuse of discretion.
Baroldy v. Ortho Pharm. Corp.,
¶ 8 “Ordinarily, a plaintiff in a medical malpractice lawsuit must prove the causal connection between an act or omission and the ultimate injury through expert medical testimony, unless the connection is readily apparent to the trier of fact.”
Barrett v. Harris,
¶ 9 The rationale behind the requirement that a plaintiff must generally offer expert testimony about
probable
causation stems from the basic principle that a plaintiff has the burden of proving his or her injuries were caused by defendant’s conduct.
See Seisinger v. Siebel,
¶ 10 In contrast, as recognized by courts in several jurisdictions, a defendant has no such burden and may choose merely to rebut plaintiffs evidence.
See, e.g., Allen v. Brown Clinic, P.L.L.P.,
¶ 11 The significance of the burden a plaintiff candes was addressed in
Wilder v. Eberhart,
¶ 12 Benkendorf asserts nonetheless that because the court in Wilder was concerned with burden shifting, that ease applies only when the burden of proof has shifted from the plaintiff to the defendant. He argues that because a defense expert only has to “rebut the cause that the victim’s medical expert has provided,” and does “not have to produce an alternate cause,” forbidding a defense causation expert from testifying about possibilities would not improperly shift the burden of proof to the defendant. We disagree.
¶ 13 Requiring defense experts to testify based only on reasonable medical probabilities would effectively prevent defendants in many cases from presenting testimony regarding causation unless their experts could declare that a particular alternate cause more probably than not was the cause of the plaintiffs injury. Consistent with the court’s observation in
Wilder,
“inequities would abound” if we were to accept Benkendorfs argument that ACSC could not rebut his prima facie malpractice case by introducing
*532
evidence regarding
other
possible causes of the injury.
See id.
at 677 (precluding testimony of possible causes would impermissibly shift the burden to defendant of proving a different specific cause of the injury);
Allen,
¶ 14 Although not cited by Benkendorf, we recognize that courts in a few jurisdictions have precluded testimony by defense experts about possible causes.
See, e.g., Iowa Power & Light Co. v. Stortenbecker,
¶ 15 Based on our review of these authorities, we agree with the majority of jurisdictions that have addressed the issue and hold that an expert witness called by the defense to testify about causation in a medical malpractice ease may testify about “possible” causes of the plaintiffs injury.
5
A defendant in such a case need not prove another cause for plaintiffs injury, but may, as ACSC did here, testify as to alternative causes tending to undercut the plaintiffs contention that the defendant’s alleged negligence more probably than not caused the injury.
See Wilder,
¶ 16 Of course, the requirements of the Arizona Rules of Evidence governing the admission of expert testimony, and our cases interpreting those rules, must still be satisfied. “[T]he evidence must be relevant, the witness must be qualified, and the evidence must be the kind that will assist the jury.”
*533
Logerquist v. McVey,
¶ 17 We therefore conclude that the trial court did not abuse its discretion when it denied Benkendorfs motion in limine. Sehroeder testified that the Coumadin dosage did not cause Judy’s brain hemorrhage and that any one or more of a number of factors he described could have caused the hemorrhage. We presume that the court determined Sehroeder was qualified to testify, his testimony was relevant, and it would assist the jury in determining causation.
7
Cf. Patterson v. Chenowth,
CONCLUSION
¶ 18 For the foregoing reasons, we conclude that ACSC’s expert could properly testify to the possible causes of Judy’s brain hemorrhage. We therefore affirm the trial court's denial of Benkendorfs motion in li-mine.
Notes
. Pursuant to Arizona Rule of Civil Appellate Procedure 28(g), we address other issues raised on appeal by Benkendorf in a separate memorandum decision filed herewith.
. As reflected by expert testimony presented at trial, a person taking Coumadin to treat a blood clot must be monitored to ensure the level of medication in the blood remains within an acceptable therapeutic range. The goal is to thin the patient’s blood so that the Coumadin is effective in treating the blood clot, but without creating an excessive risk of bleeding. The therapeutic range is commonly measured by the International Normalized Ratio (“INR”), which is a methodology of standardizing anti-coagulation levels.
. Sehroeder also referenced aneurysms, caverno-mas, head trauma, brain tumors, microaneu-rysms, venous angiomas, bruises in the brain, amyloid angiopathy, arteriovenous malformations, and malformations of brain blood vessels as possible factors.
. Under some circumstances, a plaintiff's expert may opine as to possible causes of an injury if other evidence supports a causal connection.
See Butler v. Wong,
. Consistent with the cases cited in n.4, supra, it would make little sense for us to conclude that a defendant's expert witness must always testify to probable causes, but a plaintiff’s expert could, under certain circumstances, testify as to possibilities.
. Nothing in this opinion should be construed as addressing an affirmative defense, counterclaim, or other situation where the defendant has the burden of proof.
. Benkendorf's position relating to the admissibility of Schroeder’s testimony is based on the argument that defense experts cannot opine as to possibilities. The record does not reflect, nor does Benkendorf argue on appeal, that he objected to Schroeder’s testimony on any other grounds.
